Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Brii Biosciences (BRIBY) has entered into a licensing agreement with Joincare Group for the exclusive rights to develop and commercialize BRII-693 in Greater China. BRII-693 is a novel synthetic lipopeptide designed to treat critically ill patients with multidrug-resistant gram-negative bacterial infections.
Under the agreement, Joincare will take full responsibility for development, regulatory approval, and commercialization in Greater China. Brii Bio will receive an upfront payment, milestone payments, and tiered royalties on net sales. The drug has shown promising results in Phase 1 studies, demonstrating favorable safety and tolerability profiles in both Chinese and non-Chinese participants.
The drug specifically targets infections caused by carbapenem-resistant bacteria, including Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacterales (CRE). BRII-693 has already received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China.
Brii Biosciences (BRIBY) ha stipulato un accordo di licenza con Joincare Group per i diritti esclusivi di sviluppo e commercializzazione di BRII-693 nella Grande Cina. BRII-693 猫 un nuovo lipopeptide sintetico progettato per trattare pazienti critici con infezioni da batteri gram-negativi multiresistenti.
Secondo l'accordo, Joincare si occuper脿 completamente dello sviluppo, dell'approvazione regolatoria e della commercializzazione nella Grande Cina. Brii Bio ricever脿 un pagamento iniziale, pagamenti legati a traguardi e royalties a scaglioni sulle vendite nette. Il farmaco ha mostrato risultati promettenti negli studi di Fase 1, dimostrando profili di sicurezza e tollerabilit脿 favorevoli sia nei partecipanti cinesi che non cinesi.
Il farmaco 猫 specificamente indirizzato contro infezioni causate da batteri resistenti ai carbapenemi, inclusi Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) e Enterobacterales (CRE). BRII-693 ha gi脿 ottenuto l'approvazione IND dalla CDE della NMPA per uno studio di bridging farmacocinetico di Fase 1 in Cina.
Brii Biosciences (BRIBY) ha firmado un acuerdo de licencia con Joincare Group para los derechos exclusivos de desarrollar y comercializar BRII-693 en la Gran China. BRII-693 es un nuevo lipopeptido sint茅tico dise帽ado para tratar a pacientes cr铆ticamente enfermos con infecciones bacterianas gramnegativas multirresistentes.
Bajo el acuerdo, Joincare asumir谩 la responsabilidad total del desarrollo, aprobaci贸n regulatoria y comercializaci贸n en la Gran China. Brii Bio recibir谩 un pago inicial, pagos por hitos y regal铆as escalonadas sobre las ventas netas. El f谩rmaco ha mostrado resultados prometedores en estudios de Fase 1, demostrando perfiles favorables de seguridad y tolerabilidad tanto en participantes chinos como no chinos.
El medicamento se dirige espec铆ficamente a infecciones causadas por bacterias resistentes a carbapen茅micos, incluyendo Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) y Enterobacterales (CRE). BRII-693 ya ha recibido la aprobaci贸n IND de la CDE de la NMPA para un estudio puente farmacocin茅tico de Fase 1 en China.
Brii Biosciences (BRIBY)电� Joincare Group瓿� 欷戧淡 雽�毳� 雮挫棎靹� BRII-693鞚� 臧滊皽 氚� 靸侅梾頇旍棎 雽�頃� 霃呾爯 甓岆Μ毳� 攵�鞐晿电� 霛检澊靹犾姢 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. BRII-693电� 雼れ暯鞝� 雮挫劚 攴鸽瀸 鞚岇劚攴� 臧愳椉鞙茧 鞙勲弲頃� 頇橃瀽毳� 旃橂頃橁赴 鞙勴暣 靹り硠霅� 靸堧鞖� 頃╈劚 毽彫韼╉儉鞚措摐鞛呺媹雼�.
瓿勳暯鞐� 霐半澕 Joincare电� 欷戧淡 雽�毳� 雮� 臧滊皽, 攴滌牅 鞀轨澑 氚� 靸侅梾頇旍棎 雽�頃� 鞝勳爜鞚� 毂呾瀯鞚� 歆戨媹雼�. Brii Bio电� 靹犼笁旮�, 毵堨澕鞀ろ啢 歆�旮夑笀 氚� 靾滊Г於滌棎 霐半ジ 雼硠氤� 搿滌棿韹半ゼ 氚涥矊 霅╇媹雼�. 鞚� 鞎诫鞚� 1靸� 鞐瓣惮鞐愳劀 鞙犽頃� 瓴瓣臣毳� 氤挫榾鞙茧┌, 欷戧淡鞚戈臣 牍勳甑澑 彀戈皜鞛� 氇憪鞐愳劀 鞎堨爠靹标臣 雮挫暯靹膘澊 鞖办垬頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟.
鞚� 鞎诫鞚� Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), Enterobacterales (CRE)毳� 韽暔頃� 旃措皵韼橂劥 雮挫劚 氚曧厡毽晞鞐� 鞚橅暣 氚滌儩頃樀鐢 臧愳椉鞚� 響滌爜鞙茧 頃╇媹雼�. BRII-693电� 鞚措 NMPA鞚� CDE搿滊秬韯� 欷戧淡鞐愳劀 1靸� PK 敫岆Μ歆� 鞐瓣惮毳� 鞙勴暅 IND 鞀轨澑鞚� 氚涭晿鞀惦媹雼�.
Brii Biosciences (BRIBY) a conclu un accord de licence avec Joincare Group pour les droits exclusifs de d茅velopper et commercialiser BRII-693 en Grande Chine. BRII-693 est un nouveau lipopeptide synth茅tique con莽u pour traiter les patients en 茅tat critique atteints d'infections bact茅riennes 脿 Gram n茅gatif multir茅sistantes.
Dans le cadre de cet accord, Joincare assumera l'enti猫re responsabilit茅 du d茅veloppement, de l'approbation r茅glementaire et de la commercialisation en Grande Chine. Brii Bio recevra un paiement initial, des paiements li茅s 脿 des 茅tapes cl茅s et des redevances 茅chelonn茅es sur les ventes nettes. Le m茅dicament a montr茅 des r茅sultats prometteurs lors des 茅tudes de phase 1, d茅montrant des profils de s茅curit茅 et de tol茅rance favorables chez les participants chinois et non chinois.
Le m茅dicament cible sp茅cifiquement les infections caus茅es par des bact茅ries r茅sistantes aux carbap茅n猫mes, notamment Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) et Enterobacterales (CRE). BRII-693 a d茅j脿 re莽u l'approbation IND de la CDE de la NMPA pour une 茅tude de phase 1 de pont pharmacocin茅tique en Chine.
Brii Biosciences (BRIBY) hat eine Lizenzvereinbarung mit Joincare Group abgeschlossen, die ihnen die exklusiven Rechte zur Entwicklung und Vermarktung von BRII-693 im Gro脽raum China einr盲umt. BRII-693 ist ein neuartiges synthetisches Lipopeptid, das zur Behandlung kritisch kranker Patienten mit multiresistenten gramnegativen bakteriellen Infektionen entwickelt wurde.
Im Rahmen der Vereinbarung 眉bernimmt Joincare die volle Verantwortung f眉r Entwicklung, beh枚rdliche Zulassung und Vermarktung in Gro脽china. Brii Bio erh盲lt eine Vorauszahlung, Meilensteinzahlungen und gestaffelte Lizenzgeb眉hren auf den Nettoumsatz. Das Medikament zeigte in Phase-1-Studien vielversprechende Ergebnisse mit g眉nstigen Sicherheits- und Vertr盲glichkeitsprofilen sowohl bei chinesischen als auch nicht-chinesischen Teilnehmern.
Das Medikament zielt speziell auf Infektionen durch carbapenemresistente Bakterien ab, darunter Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) und Enterobacterales (CRE). BRII-693 hat bereits die IND-Zulassung von der CDE der NMPA f眉r eine Phase-1-PK-Bridging-Studie in China erhalten.
- Strategic partnership with established player Joincare Group in Greater China market
- Upfront payment plus future milestone payments and tiered royalties to be received
- Favorable safety and tolerability profile shown in Phase 1 studies
- IND approval received from CDE of NMPA for Phase 1 PK bridging study in China
- Giving up rights to potentially valuable Greater China market
- Development and commercialization success now dependent on Joincare Group in Greater China
- Joincare Group to lead the clinical development and commercialization of BRII-693 in
Greater China - Brii Biosciences retains ex-
Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets
Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in
BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii听(颁搁础叠), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). 聽through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. 聽聽BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in
Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: "The growing threat of antimicrobial resistance in
Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, "The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor.聽Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs.
We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options."
About BRII-693
BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693.
About Brii Bio
Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including
About Joincare Group
Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development.
Forward-looking Statements
This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
View original content to download multimedia:
SOURCE Brii Biosciences Limited
FAQ
What are the terms of the licensing agreement between Brii Biosciences (BRIBY) and Joincare Group?
What is BRII-693 and what conditions does it treat?
What clinical progress has BRII-693 made so far?
How does BRII-693 differ from existing treatments?
What territories does Brii Biosciences retain rights to for BRII-693?
